This study aims to investigate a novel Centre-Adaptive Multi-Modal Fusion Framework (Cad-MMFF) that integrates clinical, ultrasound, and MRI data to improve the detection of clinically significant prostate cancer (csPCa), reduce unnecessary biopsies, and optimize MRI utilization.
Conditions: Prostate Cancer (Diagnosis)
Eligibility Criteria
Inclusion Criteria
- Ethnically Chinese men aged ≥ 50
- Suspicion of PCa \[elevated PSA (\>4-ng/ml) or abnormal DRE/PHI\] and indicated for prostate biopsy
- Obtained clinical consent (for prospectively enrolled patients only)
Exclusion Criteria
- Prior biopsy/treatments for PCa
- History of genitourinary cancer
- Poor image quality
- Incomplete imaging scans/clinical data/pathological results
Eligibility criteria are kept as the original English records from ClinicalTrials.gov; actual eligibility is determined by the research team's formal assessment and the informed consent form. Source: ClinicalTrials.gov, updated automatically every two weeks. Last synced: 2026年10月8日.